Navigation Links
Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
Date:10/24/2011

SEATTLE, Oct. 25, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. ("CTI" or the "Company") (NASDAQ and MTA: CTIC) today reported its financial results for the third quarter ended September 30, 2011.

"This has been a very exciting quarter for the Company as we move pixantrone one step closer to potential approval in both the U.S. and E.U.," noted James A. Bianco, M.D., CEO of Cell Therapeutics, Inc. "We believe the data contained in the resubmitted NDA confirms the confidence in the efficacy endpoints and also addresses the other requests made by the Food and Drug Administration (the "FDA"). With the day 180 responses regarding our MAA expected this quarter along with the expected reporting of final data on the tosedostat phase II study at the American Society of Hematology's annual meeting, the fourth quarter is shaping up to reflect the solid progress we have made in 2011."

Recent Highlights

  • Resubmitted the pixantrone NDA to the FDA for review to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") for patients who have failed two or more prior lines of therapy.
  • Announced second independent radiology assessment confirmed the statistical robustness of the PIX301 efficacy data.
  • FDA confirmed that the NDA would receive a six month review after resubmission resulting in potential accelerated approval as early as April 2012.
  • Appointed Reed V. Tuckson, M.D., F.A.C.P., to CTI's Board of Directors. Dr. Tuckson is the Executive Vice President and Chief of Medical Affairs at UnitedHealth Group, the Minnesota-based Fortune 25 diversified health care company that employs more than 87,000 people worldwide and serves more than 75 million Americans. Dr. Tuckson oversees the clinically-related programs of the company's six operating businesses and the work of more than 10,000 clinically-related personnel.  
  • Submitted Day 120 response to the European Medicine Agency's (the "EMA") Committee for Medic
    '/>"/>

  • SOURCE Cell Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
    2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
    3. Cell Therapeutics, Inc. Announces Reverse Stock Split
    4. Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
    5. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
    6. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
    7. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
    8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
    9. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
    10. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
    11. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/3/2015)... 3, 2015  ArroGen Group, an integrated advanced ... Molecular Identification™ (FMID) technology Aug. 2-8 at the ... Sacramento, Calif. FMID, ... law enforcement agents, district attorneys and government agencies ... By analyzing chemical residues on fingerprints ...
    (Date:8/3/2015)... , August 3, 2015 At ... Portland Hospital waved the shortfall of Jude ... stand normally for the first time.      ... http://photos.prnewswire.com/prnh/20150803/254229 ) The Selective Dorsal ... allowing him to carry out his wish to kick ...
    (Date:8/3/2015)... , Aug. 3, 2015  MiMedx Group, Inc. (NASDAQ: ... human amniotic tissue and patent-protected processes to develop and ... Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors ... the 35 th Annual Canaccord|Genuity Growth Conference in ... Petit, Chairman and CEO, William C. Taylor , ...
    (Date:8/3/2015)... ... August 03, 2015 , ... The ... processed to get such derivatives as ethylbenzene, a precursor to styrene, used to ... the automotive industry for the production of tyres and other components. Thus, growth ...
    Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 2Cerebral Palsy Operation by The Portland Hospital Allows a Boy to Stand Properly for the First Time 3MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 2World Benzene Market to Surpass 46 MMT by 2020, According to TechSci Research Report Published at MarketPublishers.com 3
    ... 27, 2010 , , , ... - New Trial Results on ExoSeal(TM) Vascular Closure Device Support its,Clinical Safety* and Efficacy ... Cordis Corporation, a worldwide ... Vascular Closure Device. ExoSeal(TM) incorporates a number of new,advances in technology and simplicity of ...
    ... ,,, ... 26, 2010, QIAGEN N.V. (NASDAQ: ... Prime Standard: QIA [, http://www.boerse-frankfurt.de/DE/index.aspx?pageID=35&ISIN=NL0000240000 ... an agreement with Roche Molecular Systems,Inc., ...
    ... increase crop yields and productivity, create sustainable forests and new medicines, and ... in the world,s poorest countries, will be among the recurring themes of ... Congress, June 6-11, 2010 , at the America,s Center ... , , ...
    Cached Biology Technology:CORDIS Launches ExoSeal(TM) Vascular Closure Device 2CORDIS Launches ExoSeal(TM) Vascular Closure Device 3CORDIS Launches ExoSeal(TM) Vascular Closure Device 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 2QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 3QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 4QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 5QIAGEN and Roche Settle Dispute Over Distribution Agreement for TheraScreen Companion Diagnostics 6Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 2Plant BioTech World Congress to Highlight Scientific Discoveries and Technologies Bringing New Hope to Feeding the World and Improving Lives 3
    (Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
    (Date:7/31/2015)... 2015 BGI llevará a cabo la 10ª Conferencia ... 25 de octubre de 2015, en Shenzhen, ... décimo aniversario este año. Desde su inauguración en 2006, ... anuales más influyentes del mundo en los campos de ... más dinámicas, entusiastas y amenas. ICG-10 se ...
    (Date:7/31/2015)... China , 31 de julho de 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) será realizada pela BGI de 22-25 ... . A conferência está celebrando seu ... em 2006, a ICG se tornou uma das reuniões ... um dos encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
    Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
    ... uncovered an important step in how herpes simplex virus, ... to gain entry into healthy cells and infect them. ... the effectiveness of monitoring these protein interactions using biomolecular ... the National Academy of Sciences, provide a better understanding ...
    ... Access publisher for Physics, Mathematics and Computer Science, ... DESY high-energy physics laboratories. Under these agreements ... all research published by their investigators in the ... PMC Physics A is edited by professor Ken ...
    ... connect silicon circuits with brains are under intensive ... commercial application in many areas, according to a ... Berger of the University of Southern California chaired ... of Research and Development in Brain-Computer Interfaces," published ...
    Cached Biology News:Penn researchers shine the light of venus to learn how the herpes virus invades cells 2Top physics laboratories sign up to open access with PhysMath Central 2Brain-computer link systems on the brink of breakthrough, study finds 2
    ... of the human Topoisomerase II gene. ... state of nucleic acids by passing an intact ... a separate DNA helix (1,2) . As a ... enzyme can relax negatively or positively supercoiled DNA, ...
    ... the template-directed polymerization of nucleotides into duplex ... I possesses a 3?5 exonuclease activity or ... during DNA replication, and also contains a ... to replace nucleotides in the growing strand ...
    ... is a genetically engineered Klenow polymerase in which ... removed, leaving only the 5 to 3 polymerase ... Klenow Fragment the enzyme of choice for isotopic ... random primed method, and for DNA sequencing by ...
    Request Info...
    Biology Products: